Multidrug resistance of <i>Helicobacter pylori</i> and its impact on the diagnosis and treatment of gastrointestinal diseases and countermeasures.

Xiya YAN; Canlin ZHENG; Zhihui TANG; Youjun FENG; Baoning WANG

Return

Multidrug resistance of Helicobacter pylori and its impact on the diagnosis and treatment of gastrointestinal diseases and countermeasures.

Author: Xiya YAN ¹ ; Canlin ZHENG ¹ ; Zhihui TANG ¹ ; Youjun FENG ² ; Baoning WANG ¹
Author Information

1. West China School of Basic Medical Sciences and Forensic Medicine, Sichuan University, Chengdu 610041, Sichuan, China.
2. School of Medicine, Zhejiang University, Hangzhou 310058, Zhejiang, China.
Publication Type:English Abstract
Keywords: Helicobacter pylori; intracellularization; multidrug resistance; new strategies for prevention and treatment
MeSH: Helicobacter pylori/genetics*; Humans; Drug Resistance, Multiple, Bacterial; Helicobacter Infections/microbiology*; Anti-Bacterial Agents/therapeutic use*; Gastrointestinal Diseases/drug therapy*
From: Chinese Journal of Biotechnology 2025;41(4):1240-1251
CountryChina
Language:Chinese
Abstract: Helicobacter pylori is a bacterium that can cause chronic gastritis, peptic ulcers, and other gastrointestinal diseases. The World Health Organization has classified H. pylori as a group Ⅰ carcinogen. Antibiotics are the primary clinical approach for eradicating H. pylori. However, incomplete eradication of H. pylori by antibiotics can lead to persistent infection, which is a major risk factor for the high incidence of gastric cancer. The widespread use of antibiotics has led to the emergence of multidrug resistance in H. pylori, contributing to treatment failures of chronic gastric diseases and increasing the risk of spreading resistant strains. Multidrug-resistant H. pylori has become a serious challenge in the diagnosis and treatment of gastrointestinal diseases. This paper reviews the global trends in the development of multidrug resistance in H. pylori, the underlying mechanisms, the challenges it poses to clinical diagnosis, and its impact on drug development, drawing on relevant literature and the research findings from our group. It proposes using cgt expression as a novel method for determining viable bacteria, identifying intracellularization as a new form of resistance in H. pylori, and exploring the potential of O-glycans as a therapeutic approach against H. pylori to address multidrug resistance. It provides new insights into understanding the mechanisms of H. pylori multidrug resistance and its prevention strategies, offering promising directions for future clinical treatments and antimicrobial drug development.